Autolus Therapeutics plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $117.4M+1,060.0% YoYTTM through 30 Jun 2026
Net Income -$280.2MTTM through 30 Jun 2026
Free Cash Flow -$232.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | -27.8% |
| EBITDA Margin | -203.5% |
| Operating Margin | -358.8% |
| Net Margin | -238.7% |
Returns
-161.4%ROE
-54.8%ROA
Balance Sheet Health
Debt / Equity0.73x
Current Ratio5.94x
Net Debt-$149.5Mnet cash position
Cash & Equivalents$171.4M
Quality Metrics
Altman Z-Score-4.24
Piotroski F-Score2 / 9
FCF Margin-198.3%
Rule of 40-170.7
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $75.4M
Diluted EPS-$1.06TTMFY2025: $-1.08
Dividend
No dividend
Capital Allocation
R&D Spend$112.6M
Capex Intensity6.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| AUCATZYL (obe-cel) Product Sales | $74.3M | View detailsFull year 2026 net product revenue projected to be between $120 million and $135 million. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.